Vivek Jain is recorded as Board Member at Icu Medical Inc (ICUI) since May 17, 2023 and CEO at Icu Medical Inc (ICUI). Icu Medical Inc reported in an 8-K filed May 14, 2025 a re-election or new board role (director) for Vivek Jain, on the board since at least 2023, effective May 13, 2025. Icu Medical Inc reported in an 8-K filed May 22, 2023 that Vivek Jain was appointed director, effective May 17, 2023. The proxy statement of Icu Medical Inc reports total compensation of $6,452,042 for Vivek Jain in fiscal 2025, including a base salary of $775,000. Disclosed compensation is on record for 9 fiscal years. Vivek Jain has spoken on 26 earnings calls and 3 other investor events across 1 company, most recently for Icu Medical Inc on November 5, 2026. Icu Medical Inc is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Icu Medical Inc includes Scott E. Lamb (CFO), Scott Lamb (CFO), Christian Voigtlander (COO) and 7 others.
“The Company’s stockholders elected each of the director nominees to serve as a director until the next annual meeting of stockholders or until their respective successor is duly elected and qualified.”
Icu Medical Inc Form 8-K, filed May 14, 2025
· Read the filing
“The Company's stockholders elected each of the director nominees to serve as a director until the next annual meeting of stockholders or until their respective successor is elected and qualified.”
Icu Medical Inc Form 8-K, filed May 22, 2023
· Read the filing
Vivek Jain on recent calls
“I'll walk through our Q3 revenue and earnings performance and provide some color on the businesses, and then turn it over to Brian, who will recap the full Q3 results.”
“I mean, there was obviously some news last week with some of the large companies having their own specific commentary around procedure volumes. For us, our business is tied to hospital admissions.”
“And we know it's, again, a busy earnings day, so I'll try to be brief. I'll walk through our Q2 revenue and earnings performance and provide some color on the businesses and then turn it over to Brian, who will recap the full Q2 results and detail our revised guidance for the year.”
“And we know it's a busy earnings day, so we'll try to be as brief as possible. I'll walk through our Q1 revenue and earnings performance and provide some commentary on the businesses, and then turn it over to Brian.”
